Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms

NCT05549661 · clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
25
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Mayo Clinic

Collaborators